HT

Henri Termeer

Europe, Noord-Brabant, The Netherlands, Tilburg

Description

Henri Termeer has served as a director of AVEO since April 2011 and is Chairman of the Board. He served as chairman, president and chief exe...

Investor Profile

Henri Termeer has backed more than 5 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series E rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Medical, Pharmaceutical.

Stage Focus

  • Series B (40%)
  • Series A (40%)
  • Series E (20%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Biopharma
  • Health Care
  • Health Diagnostics
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Henri Termeer frequently co-invest with?

Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 2
Advent Life Sciences
Europe, England, United Kingdom, London
Co-Investments: 3
Celgene
North America, New Jersey, United States, Summit
Co-Investments: 2
Morgan Stanley Expansion Capital
North America, New York, United States, New York
Co-Investments: 1
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 2
Draper Fisher Jurvetson
North America, California, United States, Menlo Park
Co-Investments: 1
GE Ventures
North America, California, United States, Menlo Park
Co-Investments: 1
BV
North America, California, United States, San Diego
Co-Investments: 1
Clarus Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
AllianceBernstein
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Henri Termeer?

Arrakis Therapeutics

Waltham, Massachusetts, United States

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series BApr 18, 2019
Amount Raised: $75,000,000
Arrakis Therapeutics

Waltham, Massachusetts, United States

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series AFeb 27, 2017
Amount Raised: $38,000,000
Aura Biosciences

Cambridge, Massachusetts, United States

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

BiotechnologyHealth CarePharmaceutical
Series BMar 5, 2015
Amount Raised: $21,000,000
Lysosomal Therapeutics

Cambridge, Massachusetts, United States

Lysosomal Therapeutics deliver cures for neurodegenerative diseases.

BiotechnologyHealth CareTherapeutics
Series AFeb 3, 2015
Amount Raised: $20,000,000
NanoString Technologies

Seattle, Washington, United States

NanoString Technologies provides a life science tools platform for a variety of basic research, translational medicine and IVD applications.

BiotechnologyHealth DiagnosticsMedical
Series EDec 3, 2012
Amount Raised: $15,300,000